Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility.

Uronis JM, Mühlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C. · 2009

Read Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. by Uronis JM, Mühlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2696084.txt.

Introduction

Uronis and colleagues showed in 2009 that shifting the gut's bacterial mix changes a mouse's risk of colon cancer driven by inflammation. Patients with inflammatory bowel disease develop colorectal cancer more often, but whether the microbes themselves drive the cancer step was unproven. The team built a model using mice lacking IL-10, a calming immune signal, dosed with a cancer-triggering chemical.

Sixty-two percent of those mice developed colon tumors, against 20 percent of normal mice given the same chemical. Tumor counts rose and fell with the severity of gut inflammation. Mice raised germ-free stayed tumor-free with healthy colons. Mice colonized with a single mild bacterium strain had far less inflammation and fewer tumors. Removing a key alarm pathway, MyD88, abolished tumors entirely. Changing the microbial tenants, the authors conclude, truly changes cancer susceptibility.

Catalog record

CREATORUronis JM, Mühlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE34 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2696084

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Modulation of the Intestinal Microbiota Alters Colitis-Associated Colorectal Cancer Susceptibility By Joshua M Uronis, Marcus Mühlbauer, Hans H Herfarth, Tara C Rubinas, Gieira S Jones, Christian Jobin, Stefan Bereswill Published in: PLoS ONE DOI: 10.1371/journal.pone.0006026 ABSTRACT Abstract It is well established that the intestinal microbiota plays a key role in the pathogenesis of Crohn's disease (CD) and ulcerative colitis (UC) collectively referred to as inflammatory bowel disease (IBD). Epidemiological studies have provided strong evidence that IBD patients bear increased risk for the development of colorectal cancer (CRC). However, the impact of the microbiota on the development of colitis-associated cancer (CAC) remains largely unknown. In this study, we established a new model of CAC using azoxymethane (AOM)-exposed, conventionalized-Il10−/− mice and have explored the contribution of the host intestinal microbiota and MyD88 signaling to the development of CAC. We show that 8/13 (62%) of AOM-Il10−/− mice developed colon tumors compared to only 3/15 (20%) of AOM- wild-type (WT) mice. Conventionalized AOM-Il10−/− mice developed spontaneous colitis and colorectal carcinomas while AOM-WT mice were colitis-free and developed only rare adenomas. Importantly, tumor multiplicity directly correlated with the presence of colitis. Il10−/− mice mono-associated with the mildly colitogenic bacterium Bacteroides vulgatus displayed significantly reduced colitis and colorectal tumor multiplicity compared to Il10−/− mice. Germ-free AOM-treated Il10−/− mice showed normal colon histology and were devoid of tumors. Il10−/−; Myd88−/− mice treated with AOM displayed reduced expression of Il12p40 and Tnfα mRNA and showed no signs of tumor development. We present the first direct demonstration that manipulation of the intestinal microbiota alters the development of CAC. The TLR/MyD88 pathway is essential for microbiota-induced development of CAC. Unlike findings obtained using the AOM/DSS model, we demonstrate that the severity of chronic colitis directly correlates to colorectal tumor development and that bacterial-induced inflammation drives progression from adenoma to invasive carcinoma. INTRODUCTION The ability to mount an inflammatory response following injury or exposure to foreign organisms is vital for host homeostasis and survival. However, a persistently heightened immune response such as that observed in chronic inflammatory disorders severely impairs host organ function, ultimately resulting in disease [1]. A major risk associated with chronic inflammation is increased likelihood of cancer development [2]–[4]. Crohn's disease (CD) and ulcerative colitis (UC) collectively termed inflammatory bowel disease (IBD) is the quintessential example in which chronic inflammation translates to increased cancer risk [2]. The cumulative incidence of colorectal cancer in IBD patients ranges from 7.6% to 18.4%, 30 years post-diagnosis [5]–[8]. Furthermore, epidemiological data suggest that the duration and severity of chronic colitis represent significant risk factors for colitis-associated colon cancer (CAC) [9]–[11]. Although the etiology of IBD remains to be elucidated, animal model-based studies indicate that the host intestinal microbiota triggers an immune response that is requisite for the onset of disease [12]–[15]. This uncontrolled immune response likely represents a defect in one or more immunosuppressive mechanisms intended to provide tolerance to the host intestinal microbiota, resulting in the over-production of pro-inflammatory mediators [12], [16] The concept of a balanced immunosuppressive response aimed at regulating the microbiota may be best illustrated in interleukin-10 knock-out (Il10−/−) mice. These mice, which exhibit intolerance to their intestinal microbiota develop spontaneous colitis as the result of microbial-induced activation of effector T cells [17]–[19]. The human colon harbor's as many as 36,000 bacterial species amounting to over 100 trillion aerobic and anaerobic bacteria [20], [21]. As a product of our co-evolution with bacteria, a communication system has developed that allow us to regulate one another, thereby maintaining intestinal homeostasis [21]. An integral role in the cross-talk that occurs between the human intestine and its resident microbiota is performed by innate bacterial sensors known as pattern recognition receptors (PRRs) [21]. Two main classes of PRRs have been shown to regulate communication between the intestinal epithelium and the microbiota. Toll-like receptors (TLRs) and Nod-like receptors (NLRs) serve to alert the host to the presence of bacteria in the extracellular and intracellular spaces respectively [22], [23]. Using the azoxymethane (AOM)/DSS model of CAC, Fukata and co-workers showed that TLR4 participates in the development of colorectal cancer [24]. Although interesting, this study has not directly addressed the impact of the microbiota in CAC development. Additionally, the AOM/DSS model of CAC appears to show a dissociation between the severity of intestinal inflammation and cancer development. Clearly, additional investigation of the impact of bacteria on development of CAC is needed. In this study, we utilized germ-free and gnotobiotic technology to modulate the content of the intestinal microbiota to determine the direct impact of bacteria on the development of CAC. We demonstrate that AOM-treated Il10−/− mice develop CAC in the presence of colitogenic bacteria whereas germ-free mice remain disease-free. The presence of colitis directly correlates with tumor multiplicity and acts as a promoter of colorectal cancer. Additionally, AOM-treated Il10−/−; Myd88−/− mice failed to develop colorectal tumors, indicating that bacterial signaling through the TLR/MyD88 system is required for development of CAC. RESULTS Bacterial-mediated colitis enhances colorectal tumorigenesis To investigate the role of bacterial-mediated colitis in the onset of colorectal carcinogenesis, conventionalized WT and Il10−/− mice were administered a regimen of AOM and monitored in vivo for signs of colitis and tumor development by colonoscopy at defined intervals (Fig. 1). After 16 weeks, WT mice showed no evidence of macroscopic inflammation and displayed a semi-translucent mucosa with well-defined vascularization associated with a healthy colon (Fig. 2A, left panel). In contrast, Il10−/− mice exhibited mucosal thickening and loss of apparent vasculature associated with macroscopic intestinal inflammation (Fig. 2A, middle panel). Macroscopic lesions compatible with tumors were observed in conventionalized Il10−/− mice at week 16 (Fig. 2A, right panel). To further study these lesions, histological analysis of colonic tissues was performed on WT and Il10−/− mice. We confirmed that the macroscopic lesions observed in Il10−/− mice were tumors that developed in the inflamed colon. As shown in Fig. 2B, AOM-treated Il10−/− mice showed a dramatic increase in tumor penetrance and multiplicity compared to WT mice. In our study, 8/13 (62%) of Il10−/− mice developed colon tumors compared to only 3/15 (20%) of WT mice. Furthermore, tumor multiplicity was 5-fold higher in Il10−/− mice with an average of 1- compared to only 0.2 tumors in WT mice (Fig. 2B) (p = 0.034). Of note, tumor development in Il10−/− mice was associated with enhanced intestinal inflammation as determined by histological analysis (Fig. 2C) (p<0.0001). Colonic expression of IL12p40 and TNFα mRNA were significantly elevated in Il10−/−- compared to WT mice (Fig. 2C). [Figure: Experimental timeline for AOM-induced colitis-associated colon tumorigenesis and analysis.Germ free mice were transferred to SPF conditions and allowed to acclimate for 5 weeks. Mice were given AOM injections once a week for 6 weeks (black arrowheads). Development of colitis and tumor formation was monitored by colonoscopy from weeks 4 to 18 after transfer from germ free to SPF conditions (white arrowheads). Mice were sacrificed between 18 and 20 weeks and tissues processed for histological and mRNA expression analysis.] [Figure: Analysis of tumor induction and inflammation.A. Representative examples of WT (left panel) and Il10−/− colons (middle and right panels) from AOM-treated mice 16 weeks after transfer to SPF conditions. B. Tumor penetrance and multiplicity in WT and Il10−/− mice (left and right panels) (p = 0.034). C. WT and Il10−/−

Read the complete text